◎Apex Medicalは呼吸療法製品に対するITCの最終見解を歓迎

Apex Medical Corp.

2014/7/22 13:57

◎Apex Medicalは呼吸療法製品に対するITCの最終見解を歓迎

AsiaNet 57404

共同JBN 0817 (2014.7.22)

【台北2014年7月21日PRN=共同JBN】呼吸療法、被圧部ケア分野の有力プレーヤーである台湾のApex Medical Corporation(Apex, TWSE:4106)は21日、米国際貿易委員会(USITC)が最終的な助言的見解を示し、APEXが新たに設計した製品XTシリーズの持続陽圧呼吸療法(CPAP)による加湿器およびWizard 220鼻マスクが、主要な競合社であるResMedが主張する特許請求範囲に該当しないと裁定したと発表した。APEXはさらに、2014年10月に性能を向上した睡眠時呼吸障害治療用のiCH加湿器を市販する計画を明らかにした。







Apex Medicalは自社ブランドの呼吸療法製品の大手メーカーであり、海外子会社と欧州、米国、アジア、その他海外市場におけるパートナーによるネットワークを確立して販売している。Apexは商品開発、エンジニアリング、マーケティング製品に特化して、業界スペシャリストによる専門の革新的チームを擁している。Apexは高品質のヘルスケア製品を提供するグローバルリーダーになることを目指し、テスト、検査済みで臨床的に評価された機器を提供するとともに、同社技術と知的財産権が呼吸療法市場の需要を満たすことを保証する。


PJ Hsueh

Apex Medical

Phone: +1-714-671-3818


615 Berry Street

Suite D Brea, CA 92821


ソース:Apex Medical Corp.

Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC


TAIPEI, July 21, 2014 /PRN=KYODO JBN/ --

Apex Medical Corporation (Apex, TWSE: 4106), a leading player in the

Respiratory Therapy and Pressure Area Care sectors, announces that the United

States International Trade Commission (USITC) has issued a final advisory

opinion, determining that Apex's newly designed XT series continuous positive

airway pressure (CPAP) water tank and Wizard 220 mask are free from the patent

claims asserted by ResMed, one of Apex's major competitors. Apex further

declares its plan of introducing an upgraded iCH water tank to the market in

October 2014.

In September 2013 Apex requested the USITC to declare that Apex's newly

designed sleep-disorder breathing treatment products are not covered by the

claims of seven ResMed patents that were raised in an earlier Section 337

investigation. On July 18, 2014, the USITC issued the final opinion in response

to the parties' appeals on the initial opinion of the Administrative Law Judge

(ALJ) issued one month earlier.

In the final and non-appealable opinion, the USITC upheld the ALJ's ruling on

the new mask design, confirming that the mask design is clear of ResMed's

asserted claims. Significantly, the USITC overruled the ALJ's negative finding

regarding the newly designed XT series water tank; the USITC determined that

the new XT series CPAP water tank is free from ResMed's patent assertions. The

USITC affirmed ALJ's finding that the petitioned water tank design for iCH

series CPAP is covered by a single claim of one ResMed patent.

Meanwhile, the United States Patent and Trademark Office (USPTO) is reviewing

the validity of five ResMed's patents, including the claim relevant to the iCH

series water tank, through a procedure named inter partes review. The USPTO is

expected to render its decisions by early 2015.

"The USITC's decision confirms our masks and XT series are clear of ResMed's

interference with patents. The demand of our products remains strong," said

Apex's CEO, Daniel Lee. "The decision is a significant approval for our

products and R&D. We deem it a victory for our customers as well as people

suffering from sleep apneas," Daniel said.

The company stresses its goal of serving patients suffering from sleeping

disorders with quality, effective as well as cost-saving CPAP products, and

affirms its devotion to innovation and its commitment to the customers.


About Apex

Apex Medical is a leading manufacturer of its own brand of Respiratory Therapy

products and distributes through an established network of international

subsidiaries and partners in Europe, the United States, Asia and other

international markets. Apex specializes in product development, engineering and

marketing products with a dedicated and innovative team of industry

professionals. Apex aims to be a global leader in the provision of high quality

healthcare products, delivering tested, trialed and clinically evaluated

devices while ensuring that its own technology and intellectual property meet

the demands of the Respiratory Therapy market.


PJ Hsueh

Apex Medical

Phone: +1-714-671-3818


615 Berry Street

Suite D Brea, CA 92821


SOURCE  Apex Medical Corp.